105 related articles for article (PubMed ID: 9267101)
1. Taxotere becomes first drug to outperform Adriamycin.
Ir Med J; 1997; 90(4):156. PubMed ID: 9267101
[No Abstract] [Full Text] [Related]
2. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Anand A; Anand A
J Natl Cancer Inst; 1995 Nov; 87(21):1642. PubMed ID: 7563210
[No Abstract] [Full Text] [Related]
3. Taxoids in combination chemotherapy for metastatic breast cancer.
Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; Pouillart P
Anticancer Drugs; 1996 Aug; 7 Suppl 2():47-52. PubMed ID: 8862712
[TBL] [Abstract][Full Text] [Related]
4. Taxotere shows significant antitumor activity in anthracycline-resistant breast cancer patients.
Oncology (Williston Park); 1994 Sep; 8(9):112. PubMed ID: 7993720
[No Abstract] [Full Text] [Related]
5. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere).
Cheson BD; Arbuck SG; Phillips PH
Oncology (Williston Park); 1993 Sep; 7(9):51-2. PubMed ID: 8105859
[No Abstract] [Full Text] [Related]
7. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
Paridaens R
Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
Zoli W; Flamigni A; Frassineti GL; Bajorko P; De Paola F; Milandri C; Amadori D; Gasperi-Campani A
Breast Cancer Res Treat; 1995 Apr; 34(1):63-9. PubMed ID: 7749161
[TBL] [Abstract][Full Text] [Related]
9. The role of taxanes in the management of breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 8):1-3. PubMed ID: 10403466
[No Abstract] [Full Text] [Related]
10. Conclusion: the place of docetaxel (Taxotere) in future therapy.
Khayat D
Anticancer Drugs; 1996 Aug; 7 Suppl 2():53. PubMed ID: 8862713
[No Abstract] [Full Text] [Related]
11. Evolution in the treatment of advanced breast cancer.
Crown J
Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
[TBL] [Abstract][Full Text] [Related]
12. The clinical rationale for developing docetaxel (Taxotere).
Armand JP
Anticancer Drugs; 1996 Aug; 7 Suppl 2():37-9. PubMed ID: 8862710
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
14. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
Verweij J
Br J Cancer; 1994 Aug; 70(2):183-4. PubMed ID: 7914419
[No Abstract] [Full Text] [Related]
16. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
17. [Taxenes: a new hope of clinical oncology in the 90-ies].
Shparik IV
Vopr Onkol; 1995; 41(1):7-12. PubMed ID: 7667946
[No Abstract] [Full Text] [Related]
18. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Kris MG; Millward M
Semin Oncol; 1999 Jun; 26(3 Suppl 10):1-2. PubMed ID: 10437742
[No Abstract] [Full Text] [Related]
19. Docetaxel (Taxotere): a highly active taxoid with manageable toxicity.
Aapro MS
Semin Oncol; 1995 Apr; 22(2 Suppl 4):1-2. PubMed ID: 7740325
[No Abstract] [Full Text] [Related]
20. Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Vogelzang NJ
Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-2. PubMed ID: 10604260
[No Abstract] [Full Text] [Related]
[Next] [New Search]
